Detail page

Knowledge Web

Person

Edgar Jost (1970-)

Arzt

Name	Edgar Jost
Time	1970- (Date of birth and death)
Place	Waismes (Belgien) (Geburtsort) Belgien
Gender	männlich
Academic degree	Dr. med. habil.
Profession	Arzt (characteristic profession) Privatdozent
Variant	E. Jost
Further information	Habilitation im Fachbereich Innere Medizin; Facharzt für Innere Medizin, Schwerpunkt Hämatologie und Internistische Onkologie
Source	Vorlage, Internet
Record type	Person
GND-Identifier	141230614
Record ID	141230614
Involved in show all Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysis Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings ZIP10 as a potential therapeutic target in acute myeloid leukaemia Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries Bone marrow biopsy in geriatric patients above the age of 85 years: invaluable or unnecessary? A retrospective analysis Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German Registry for Stem Cell Transplantation Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries Bone marrow biopsy in geriatric patients above the age of 85 years: invaluable or unnecessary? A retrospective analysis Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience Correction: Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation Impaired overall survival in young patients with acute myeloid leukemia and variants in genes predisposing for myeloid malignancies Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry Novel homozygous nonsense mutation in the P5′N-1 coding gene as an alternative cause for hereditary anemia with basophilic stippling Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents — a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature Patients with acute myelogenous leukemia (AML) from a socially disadvantaged environment show poorer therapeutic outcome A three-gene expression-based risk score can refine the European LeukemiaNet AML classification CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo Vorteil für allogene Stammzelltransplantation DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML) DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia MicroRNA expression profiles of serum from patients before and after chemotherapy MicroRNAs and Metabolites in Serum Change after Chemotherapy: Impact on Hematopoietic Stem and Progenitor Cells Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro Serum after Autologous Transplantation Stimulates Proliferation and Expansion of Human Hematopoietic Progenitor Cells Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation Antineoplastic Chemotherapy in Cancer Patients with Methicillin-Resistant Staphylococcus aureus (MRSA)

Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

Katalog der Deutschen Nationalbibliothek

Edgar Jost (1970-)

Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis

Induction chemotherapy with CPX-351 in acute myeloid leukemia: revisiting the role of early bone marrow assessment

Allogeneic hematopoietic cell transplantation after infection with SARS-CoV-2 during the COVID-19 pandemic: a multicenter retrospective analysis

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study

Impact of TP53 mutation status in elderly AML patients when adding all‐trans retinoic acid or valproic acid to decitabine

Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia

Young unrelated donors confer a survival advantage for patients with myeloid malignancies compared to older siblings

ZIP10 as a potential therapeutic target in acute myeloid leukaemia

Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries

Bone marrow biopsy in geriatric patients above the age of 85 years: invaluable or unnecessary? A retrospective analysis

Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German Registry for Stem Cell Transplantation

Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries

Bone marrow biopsy in geriatric patients above the age of 85 years: invaluable or unnecessary? A retrospective analysis

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT

Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience

Correction: Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis

Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation

Impact of trisomy 19 on outcome according to genetic makeup in patients with acute myeloid leukemia

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors

Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

Impaired overall survival in young patients with acute myeloid leukemia and variants in genes predisposing for myeloid malignancies

Impaired Overall Survival in Young Patients With Acute Myeloid Leukemia and Variants in Genes Predisposing for Myeloid Malignancies

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

Novel homozygous nonsense mutation in the P5′N-1 coding gene as an alternative cause for hereditary anemia with basophilic stippling

Correction to: Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study

Investigation of measurable residual disease in acute myeloid leukemia by DNA methylation patterns

Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents — a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Presence of TERT Promoter Mutations is a Secondary Event and Associates with Elongated Telomere Length in Myxoid Liposarcomas

Evidence for a pre-existing telomere deficit in non-clonal hematopoietic stem cells in patients with acute myeloid leukemia

Perioperative intravenous immunoglobulin treatment in a patient with severe acquired von Willebrand syndrome: case report and review of the literature

Patients with acute myelogenous leukemia (AML) from a socially disadvantaged environment show poorer therapeutic outcome

A three-gene expression-based risk score can refine the European LeukemiaNet AML classification

CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo

Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo

Vorteil für allogene Stammzelltransplantation

DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML)

DNA-methylation in C1R is a prognostic biomarker for acute myeloid leukemia

MicroRNA expression profiles of serum from patients before and after chemotherapy

MicroRNAs and Metabolites in Serum Change after Chemotherapy: Impact on Hematopoietic Stem and Progenitor Cells

Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms

Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation

Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation

Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia

Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro

Serum after Autologous Transplantation Stimulates Proliferation and Expansion of Human Hematopoietic Progenitor Cells

Ubiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation

Antineoplastic Chemotherapy in Cancer Patients with Methicillin-Resistant Staphylococcus aureus (MRSA)